Severe Malaria

23 registered clinical trials studyying Severe Malaria — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	PDMC Implementation Trial in Kenya NCT06624631	Liverpool School of Tropical Medicine	Phase 4
Recruiting	Post-discharge Malaria Chemoprevention Implementation Trial in Benin NCT06601712	Institut de Recherche Clinique du Benin	Phase 4
Recruiting	Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Disc NCT07082205	Liverpool School of Tropical Medicine	Phase 3
Not Yet Recruiting	Enhancing Pediatric Acute Care Through Adaptive E-Learning and In-Person Skills Practice in Tanzania NCT06635733	Stanford University	N/A
Enrolling By Invitation	Severe Malaria in Remote Areas- Closing the Evidence Gap NCT06806956	Tropical Diseases Research Centre, Zambia	—
Recruiting	Platelet-Directed Whole Blood Transfusion Strategy for Malaria NCT05711485	Johns Hopkins Bloomberg School of Public Health	N/A
Completed	Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX NCT06064591	Institute of Tropical Medicine, Belgium	—
Completed	Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate NCT05140278	University of Oxford	Phase 2
Unknown	Association of Diabetes and Metabolic Syndrome With Severe Malaria in Cameroon NCT05685875	Karolinska Institutet	—
Completed	To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmo NCT04675931	Novartis Pharmaceuticals	Phase 2
Unknown	Effect of Paracetamol on Kidney Function in Severe Malaria NCT04251351	University of British Columbia	Phase 3
Completed	Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children NCT04473768	Institute of Tropical Medicine, Belgium	—
Completed	Very Severe Malaria Treated by Intravenous Artesunate NCT04516317	Dr Fabrice BRUNEEL	—
Completed	Lung Ultrasound in Children With Severe Malaria NCT04176029	University of Oxford	—
Completed	Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR C NCT04037332	Swiss Tropical & Public Health Institute	—
Completed	Clinical Prediction Models for Pediatric In-Hospital Death Risk in Congolese Severe Malaria Children Using Mac NCT07355426	University of Kinshasa	—
Completed	Severe and Cerebral Malaria Investigated Through Host Metabolomics NCT02451904	University of Oxford	—
Completed	Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With NCT01955382	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Malaria Treatment With Injectable ArteSunate NCT01828333	Swiss Tropical & Public Health Institute	—
Completed	Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial NCT01255215	University Health Network, Toronto	Phase 1 / Phase 2
Unknown	Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment NCT01122134	Makerere University	—
Completed	Examination of Protective Factors Against Severe Malaria NCT00342043	National Institute of Allergy and Infectious Diseases (NIAID)	—
Completed	Severe Malaria and Anti-malarial Drug Resistance in Cambodia NCT00341003	National Institute of Allergy and Infectious Diseases (NIAID)	—